Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC.

Journal for immunotherapy of cancer - 1 Feb 2022

Schuurbiers Milou, Huang Zhongyun, Saelee Senglor, Javey Manana, de Visser Leonie, van den Broek Daan, Heuvel Michel van den, Lovejoy Alexander F, Monkhorst Kim, Klass Daniel

Abstract excerpt

BACKGROUND: Patients treated with immunotherapy are at risk of considerable adverse events, and the ongoing struggle is to accurately identify the subset of patients who will benefit. Tumor mutational burden (TMB) has emerged as a promising predictive biomarker but requires tumor tissue which is not always available. Blood-based TMB (bTMB) may provide a minimally invasive assessment of mutational load. However,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Immunotherapy

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 35217576
DOI: 10.1136/jitc-2021-004064
PMCID: PMC8883268

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC.PMID 35217576Read ↗

Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung CancerSemantic proximity Read ↗

Exploring real-world concordance of tissue mutation burden (TMB) from blood and tissue in patients with solid tumorsSemantic proximity Read ↗

Clinical and technical insights of tumour mutational burden in non-small cell lung cancer.Semantic proximity Read ↗

Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing.Semantic proximity Read ↗

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.Semantic proximity Read ↗

Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore.Semantic proximity Read ↗

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.Semantic proximity Read ↗

New methodology of TMB assessment from tissue and liquid biopsy in NSCLC.Semantic proximity Read ↗

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.Semantic proximity Read ↗

Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB2 harmonization project comparing three NGS panels.Semantic proximity Read ↗

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.Semantic proximity Read ↗

Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.